Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti

master's thesis

• Title (english): Novel pharmacotherapy possibilities for treatment of Alzheimer disease
• Author: Klara Vicić
• Mentor: Petra Turčić (mentor)
• Committee member: Petra Turčić (predsjednik povjerenstva)
• Committee member: Lidija Bach-Rojecky (član povjerenstva)
• Committee member: Daniela Amidžić Klarić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology); Zagreb
• Defense date and country: 2024-07-18, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Alzheimerova bolest (AD) je progresivna neurodegenerativna bolest koja uzrokuje značajan pad kognitivnih funkcija i
kvalitete života oboljelih. Ovaj diplomski rad istražuje farmakoterapijske mogućnosti liječenja AD-a, uključujući
postojeće i nove pristupe. Rad se fokusira na nekoliko ključnih aspekata:
1. Inhibitori acetilkolinesteraze: Donepezil, rivastigmin i galantamin su odobreni lijekovi koji djeluju
povećanjem razine acetilkolina u mozgu, što može privremeno poboljšati ili stabilizirati simptome AD-a.
2. Antagonisti NMDA receptora: Memantin je lijek koji se koristi za liječenje umjerene do teške AD-a,
djelujući na glutamatni sustav kako bi se smanjila neurotoksičnost.
3. Prirodni nootropici: Istraženi su prirodni spojevi poput ginka, ginsenga, bakope i kurkume, koji imaju
potencijalne neuroprotektivne učinke.
4. Novija saznanja iz kliničkih studija: Proučeni su novi lijekovi poput adukanumaba, lekanemaba,
donanemaba i AXS-05 koji ciljaju različite patofiziološke mehanizme AD-a, uključujući smanjenje
amiloidnih plakova i upalnih procesa.
Zaključno, unatoč trenutnom nedostatku lijeka koji bi mogao zaustaviti ili preokrenuti tijek AD-a, istraživanja u
farmakoterapiji pružaju nadu za budućnost u smislu boljeg upravljanja simptomima i poboljšanja kvalitete života
oboljelih. Potrebna su daljnja istraživanja kako bi se razvili učinkoviti tretmani koji bi ciljali temeljne uzroke bolesti.

Abstract (english)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that significantly impairs cognitive functions and
quality of life. This thesis explores the pharmacotherapeutic options for treating AD, including existing and emerging
approaches. The study focuses on several key aspects:
1. Acetylcholinesterase inhibitors: Donepezil, rivastigmine, and galantamine are approved drugs that work by
increasing acetylcholine levels in the brain, which can temporarily improve or stabilize AD symptoms.
2. NMDA receptor antagonists: Memantine is used for moderate to severe AD, acting on the glutamate system
to reduce neurotoxicity.
3. Natural nootropics: Natural compounds such as ginkgo, ginseng, bacopa, and turmeric are explored for their
potential neuroprotective effects.
4. Recent findings from clinical studies: New drugs like aducanumab, lecanemab, donanemab, and AXS-05 are
studied, targeting various AD pathophysiological mechanisms, including reducing amyloid plaques and
inflammatory processes.
In conclusion, despite the current lack of a cure to halt or reverse AD progression, pharmacotherapy research offers
hope for better symptom management and improved quality of life for patients. Further research is needed to develop
effective treatments targeting the underlying causes of the disease.

• Keywords: Alzheimerova bolest; inhibitori acetilkolinesteraze; antagonisti NMDA receptora; kliničke studije faze III
• Keywords (english): Alzheimer's disease; acetylcholinesterase inhibitors; NMDA receptor antagonists; clinical trials phase III
• Language: croatian
• URN:NBN: urn:nbn:hr:163:726042
• Study programme: Title: Pharmacy - integrated undergraduate and graduate - university study; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: sveučilišni magistar farmacije (sveučilišni magistar farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2024-09-26 12:33:35